Fertility startup Gameto has received permission from the FDA to see if its ovary-in-a-dish technology can make in vitro ...
Teva CEO Richard Francis expects continued growth for Austedo despite future Medicare price negotiations, maintaining $2.5B ...
VC, a venture capital firm that has spread its bets across multiple industries, including biotech and digital health, is ...
The Trump administration said on Wednesday it will consider “opportunities to bring greater transparency” to the ...
The first of two confirmation hearings is now underway for Robert F. Kennedy, Jr. to serve as President Donald Trump’s HHS ...
Embattled genetics testing giant 23andMe is thinking of selling itself as it runs out of cash. The company needs ...
Zentalis Pharmaceuticals is axing about 40% of its staff and doubling down on advancing its only pipeline candidate as part ...
A Delaware judge issued a split ruling in a bizarre legal squabble over the IPO plans of Aurion Biotech, which should allow ...
Lonza said Wednesday morning it is on the hunt for deals to increase its capacity and technology offerings, which comes after ...
Curie.Bio reveals $340M seed fund, Cullinan's zipalertinib succeeds in lung cancer trial, Benchling cuts 10% staff, I-Mab reduces workforce, Regulus shares Phase 1b data, Imvax raises $29M ...
Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to Endpoints News.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback